Inventiva (IVA) News Today → Make This $3 Trade the Instant the Opening Bell Rings (From Monument Traders Alliance) (Ad) Free IVA Stock Alerts $4.36 +0.16 (+3.81%) (As of 03/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePRISM MarketView Spotlights Companies Leading the Charge in Liver Disease Treatment Following Landmark FDA Approvalmarkets.businessinsider.com - March 18 at 5:41 PMInventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2Dglobenewswire.com - March 18 at 4:00 PMMadrigal: Accelerated Rezdiffra Approval Puts It In The NASH Leadseekingalpha.com - March 18 at 12:41 PMShares of Madrigal Pharmaceuticals soar on FDA approval for NASH treatmentbizjournals.com - March 14 at 6:45 PMInventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2Dglobenewswire.com - March 13 at 4:00 PMInventiva’s Clinical Progress and Financial Valuation Reinforce Buy Ratingmarkets.businessinsider.com - March 8 at 2:44 PMInventiva’s Buy Rating Affirmed: Swift Management Actions and Strong Safety Profile Signal Promising Outlookmarkets.businessinsider.com - March 8 at 12:40 AMInventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumedglobenewswire.com - March 7 at 4:00 PMInventiva S.A. (NASDAQ:IVA) to Post FY2023 Earnings of ($2.26) Per Share, HC Wainwright Forecastsmarketbeat.com - February 23 at 6:34 AMBuy Rating for Inventiva Despite Temporary Trial Setback: Analyst Sees Isolated Incident and Strong Safety Recordmarkets.businessinsider.com - February 17 at 7:54 PMInventiva halt recruitment for Phase III NASH trial following adverse eventmsn.com - February 16 at 2:03 PMStifel Nicolaus Cuts Inventiva (NASDAQ:IVA) Price Target to $25.00marketbeat.com - February 16 at 10:49 AMInventiva Stock Falls 20% After Pausing Screening, Randomization in Trial Due to Adverse Eventmarketwatch.com - February 16 at 9:03 AMINVENTIVA: Inventiva reports preliminary 2023 fiscal year financial Information and provides an update on its clinical trial NATiV3finanznachrichten.de - February 15 at 6:00 PMInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3finance.yahoo.com - February 15 at 6:00 PMInventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3globenewswire.com - February 15 at 4:35 PM11 of the Best Investing Books for Beginnersmsn.com - February 6 at 5:47 PMInventiva S.A. (NASDAQ:IVA) Receives Consensus Rating of "Buy" from Brokeragesmarketbeat.com - February 4 at 5:10 AMFDA accepts Adaptimmune BLA for afami-cel, decision expected by Aug. 4msn.com - January 31 at 9:47 PMInventiva SA ADR IVAmorningstar.com - January 31 at 5:48 PMHalf-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreuxmarkets.businessinsider.com - January 24 at 8:07 PMINVENTIVA: Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreuxfinanznachrichten.de - January 24 at 5:07 PMNon-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsightfinance.yahoo.com - January 17 at 5:48 PMInventiva S.A. (NASDAQ:IVA) Short Interest Updatemarketbeat.com - January 17 at 6:18 AMINVENTIVA: Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bankfinanznachrichten.de - January 10 at 7:29 PMInventiva (NASDAQ:IVA) Earns "Outperform" Rating from Lifesci Capitalmarketbeat.com - January 9 at 8:31 AMAnalysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Annexon Biosciences (ANNX)markets.businessinsider.com - December 21 at 11:01 PMInventiva (NASDAQ:IVA) Price Target Lowered to $24.00 at HC Wainwrightmarketbeat.com - December 21 at 8:22 AMInventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development programfinance.yahoo.com - December 20 at 7:26 PMInventiva S.A. (NASDAQ:IVA) Sees Large Decline in Short Interestmarketbeat.com - December 17 at 2:56 PMInventiva S.A. (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Analystsmarketbeat.com - December 16 at 6:43 AMSEC Green Lights Public Listing Of Texas Cannabis Co. That Will Use AI In Clinical Trialsmsn.com - December 15 at 7:35 PMInventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASHfinance.yahoo.com - December 4 at 8:24 PMAnalysts’ Top Healthcare Picks: Morphosys Ag (MOR), Abbott Labs (ABT)markets.businessinsider.com - November 22 at 10:12 PMINVENTIVA: Inventiva reports 2023 Third Quarter Financial Informationfinanznachrichten.de - November 21 at 8:14 PMInventiva reports 9M resultsmsn.com - November 21 at 8:14 PMInventiva reports 2023 Third Quarter Financial Information¹finance.yahoo.com - November 21 at 4:10 PMInventiva Share Price (IVA.PA)lse.co.uk - November 12 at 1:44 PMHold Rating on Madrigal Pharmaceuticals Amid Potential and Uncertainties: FDA Review, Commercial Launch, and Mixed Data Impactmarkets.businessinsider.com - November 9 at 10:15 AMInventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023finance.yahoo.com - November 6 at 6:25 PMNon-alcoholic Steatohepatitis Market to grow by USD 11.22 billion from 2022 to 2027, North America to account for 51% of market growth- Technaviofinance.yahoo.com - October 27 at 7:17 PMPositive Prospects for Inventiva: Pivotal NATiV3 Trial Progress, Anticipated LEGEND Study Results, and Expansion into Asian Marketsmarkets.businessinsider.com - October 2 at 9:36 AMINVENTIVA: Inventiva reports its 2023 first-half financial results and provides a corporate updatefinanznachrichten.de - September 28 at 6:58 PMInventiva reports its 2023 first-half financial results and provides a corporate updatefinance.yahoo.com - September 28 at 6:58 PMInventiva (IVA) to Release Quarterly Earnings on Thursdaymarketbeat.com - September 22 at 8:50 AMInvestors Eye CymaBay's AFFIRM Study As Regulatory Uncertainties Easemarkets.businessinsider.com - September 21 at 7:08 PMPre-market Movers: MURF, IFRX, NEPT, UPTD, AEHL…markets.businessinsider.com - September 21 at 8:24 AMInventiva ADRs Rise 9% Following Licensing Dealmarketwatch.com - September 20 at 7:02 PMInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Koreafinance.yahoo.com - September 20 at 7:02 PMInventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Koreafinance.yahoo.com - September 20 at 7:02 PM Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Did you make $29,000 two days with AI options trades? (Ad)What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below: Click Here To Get Your Free Copy IVA Media Mentions By Week IVA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVA News Sentiment▼0.420.62▲Average Medical News Sentiment IVA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVA Articles This Week▼62▲IVA Articles Average Week Get Inventiva News Delivered to You Automatically Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RENB News Today GBIO News Today ABEO News Today MACK News Today SPRB News Today OPTN News Today ALIM News Today OVID News Today VRCA News Today RPTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IVA) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Companytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.